UK markets close in 26 minutes
  • FTSE 100

    7,749.53
    -11.58 (-0.15%)
     
  • FTSE 250

    19,972.03
    +56.52 (+0.28%)
     
  • AIM

    867.03
    +1.62 (+0.19%)
     
  • GBP/EUR

    1.1401
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2369
    -0.0038 (-0.30%)
     
  • BTC-GBP

    18,599.13
    -76.52 (-0.41%)
     
  • CMC Crypto 200

    520.91
    +3.90 (+0.75%)
     
  • S&P 500

    4,054.04
    -6.39 (-0.16%)
     
  • DOW

    33,875.73
    -73.68 (-0.22%)
     
  • CRUDE OIL

    80.65
    -0.36 (-0.44%)
     
  • GOLD FUTURES

    1,921.60
    -8.40 (-0.44%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     
  • HANG SENG

    22,688.90
    +122.12 (+0.54%)
     
  • DAX

    15,123.13
    -9.72 (-0.06%)
     
  • CAC 40

    7,086.88
    -9.11 (-0.13%)
     

Linnea SA Receives Swiss Narcotics License allowing for the Production and Exportation of High THC Active Pharmaceutical Ingredients

Linnea
Linnea

Swissmedic grants Linnea a narcotics license allowing them to now be one of the first to produce and export GMP Certified High THC APIs.

RIAZZINO, Switzerland, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Linnea SA (“Linnea,” or “the Company”), a leading pharmaceutical manufacturer with over 40 years of experience, has been granted a narcotics license by Swissmedic at the end of 2022. They are now one of the first companies in Switzerland to be able to produce and export high THC APIs. The Company will begin producing GMP-certified high-THC active pharmaceutical ingredients (APIs) in 2023, becoming one of the first Swiss companies to do so.

At the forefront of this exciting licensing is Linnea Cannabinoids, a project of Linnea SA. Linnea Cannabinoids aims to manufacture the highest-quality pharmaceutical cannabinoid ingredients and drive research and innovation within the global industry.

Gaining a narcotics license will allow Linnea to export their standardized and innovative high-THC APIs anywhere in the world where the importation of these products is legal. The demand for GMP certified pharmaceutical-grade cannabis is higher than ever. With this license, Linnea will be able to meet the demand of customers and patients worldwide.

“We are so honored to be granted a narcotics license in Switzerland, this opens up many new commercial possibilities for Linnea Cannabinoids and our customers,” says Susanne Caspar, CEO of Linnea SA. “High-quality cannabinoid ingredients are essential to producing the pharmaceutical products that patients need, and we are eager to contribute our expertise to this effort. We look forward to the opportunities this will afford us in creating new partnerships and continuing to innovate in the industry.”

As we enter a new year, Linnea SA is expanding its portfolio and bringing its pharmaceutical cannabinoid products to a wider global audience. You can find Linnea online here and contact them here.

About Linnea Cannabinoids:
Linnea has been providing gold-standard botanical ingredients for use in the pharmaceutical, cosmetics and dietary supplement industries for over 40 years. Having expanded into the cannabis and cannabinoid industries in 2016, they helped pave the way in research, standardization and a pharmaceutical level of quality for this emerging global industry.

MEDIA CONTACT:
Lucas Wentworth
NisonCo Marketing
Lucas@NisonCo.com